Oxytocin to Decrease Blood Loss During Cesarean Section
Completed
American University of Beirut Medical Center
N/A
2012-07-01
The goal of this study is to determine the best dose of a drug called oxytocin, that is
usually used to stop bleeding during a delivery, when used during a cesarean delivery. It
will be administered during cesarean section in order to decrease the amount blood loss. The
investigators are proposing to have 3 groups of subjects each given a different safe dose of
oxytocin and then to assess the effectiveness of each regimens on the amount blood lost
during cesarean sections.This will let use know which is the best lowest dose needed.
Outcomes After the Implementation of a New Oxytocin Protocol
Completed
C.R.Darnall Army Medical Center
N/A
2016-04-01
The proposed study is a prospective, randomized, active control, open label study. One
hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one
of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group.
The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion
according to a stepwise algorithm following delivery of the placenta. The standard practice
group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of
30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary
outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of
time required to establish adequate uterine tone following the delivery of the infant, total
dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss
based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes
include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider,
use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side
effects (nausea, chest tightness/pain, and ST-segment changes).
The purpose of this research study is to determine if low-dose (i.e., a fraction of what is
commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
